Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma

Introduction: Glaucoma refers to chronic diseases that require constant treatment. Conservative treatment of glaucoma involves the continuous assigning of local hypotensive medications for a long time to maintain normal range of intraocular pressure (IOP). Objective: To examine the efficacy of La...

Full description

Bibliographic Details
Main Authors: Shambra SV, Korol AR
Format: Article
Language:English
Published: Ukrainian Society of Ophthalmologists 2015-10-01
Series:Journal of Ophthalmology
Subjects:
Online Access:https://www.ozhurnal.com/en/archive/2015/5/12-fulltext
_version_ 1797354067362578432
author Shambra SV
Korol AR
author_facet Shambra SV
Korol AR
author_sort Shambra SV
collection DOAJ
description Introduction: Glaucoma refers to chronic diseases that require constant treatment. Conservative treatment of glaucoma involves the continuous assigning of local hypotensive medications for a long time to maintain normal range of intraocular pressure (IOP). Objective: To examine the efficacy of Latanoks medication in clinical practice with patients having primary open-angle glaucoma. Material and methods: 20 patients (30 eyes) have been under the observation with primary open-angle glaucoma stage I-III. All the patients were transferred to Latanoks monotherapy due to the lack of the intraocular pressure compensation. Tonometry, tonography, electronic static perimetry were performed at the beginning and the end of the observation period. Results: The use of Latanoks medication for the treatment of patients with an open-angle glaucoma within three months has led to a decrease of tonography Po index from an average (20.0 ± 6.0) mm Hg to (14.9 ± 3.0) mm Hg (p < 0.0003). The use of Latanoks for the treatment of patients with open-angle glaucoma within three months has led to a decrease of IOP (by Maklakov) from an average (22.8 ± 5.0) mm Hg. to (17.6 ± 2.0) mm Hg (p < 0.0002) and also has allowed to keep the visual field indicators stable for three months. Conclusion: Latanoks is an effective hypotensive medication that does authentically lower IOP and helps to save the visual field.
first_indexed 2024-03-08T13:39:56Z
format Article
id doaj.art-1373861a4a6246bd8ca58f6eb080ee82
institution Directory Open Access Journal
issn 2412-8740
language English
last_indexed 2024-03-08T13:39:56Z
publishDate 2015-10-01
publisher Ukrainian Society of Ophthalmologists
record_format Article
series Journal of Ophthalmology
spelling doaj.art-1373861a4a6246bd8ca58f6eb080ee822024-01-16T10:06:15ZengUkrainian Society of OphthalmologistsJournal of Ophthalmology2412-87402015-10-015687110.31288/oftalmolzh201556871Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucomaShambra SV0Korol AR1Filatov Eye Disease and Tissue Therapy Institute, the NAMS of UkraineFilatov Eye Disease and Tissue Therapy Institute, the NAMS of UkraineIntroduction: Glaucoma refers to chronic diseases that require constant treatment. Conservative treatment of glaucoma involves the continuous assigning of local hypotensive medications for a long time to maintain normal range of intraocular pressure (IOP). Objective: To examine the efficacy of Latanoks medication in clinical practice with patients having primary open-angle glaucoma. Material and methods: 20 patients (30 eyes) have been under the observation with primary open-angle glaucoma stage I-III. All the patients were transferred to Latanoks monotherapy due to the lack of the intraocular pressure compensation. Tonometry, tonography, electronic static perimetry were performed at the beginning and the end of the observation period. Results: The use of Latanoks medication for the treatment of patients with an open-angle glaucoma within three months has led to a decrease of tonography Po index from an average (20.0 ± 6.0) mm Hg to (14.9 ± 3.0) mm Hg (p < 0.0003). The use of Latanoks for the treatment of patients with open-angle glaucoma within three months has led to a decrease of IOP (by Maklakov) from an average (22.8 ± 5.0) mm Hg. to (17.6 ± 2.0) mm Hg (p < 0.0002) and also has allowed to keep the visual field indicators stable for three months. Conclusion: Latanoks is an effective hypotensive medication that does authentically lower IOP and helps to save the visual field.https://www.ozhurnal.com/en/archive/2015/5/12-fulltextglaucomatonometryvisual fieldintraocular pressure
spellingShingle Shambra SV
Korol AR
Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma
Journal of Ophthalmology
glaucoma
tonometry
visual field
intraocular pressure
title Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma
title_full Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma
title_fullStr Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma
title_full_unstemmed Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma
title_short Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma
title_sort efficacy of latanoks latanaprost 0 005 in patients with open angle glaucoma
topic glaucoma
tonometry
visual field
intraocular pressure
url https://www.ozhurnal.com/en/archive/2015/5/12-fulltext
work_keys_str_mv AT shambrasv efficacyoflatanokslatanaprost0005inpatientswithopenangleglaucoma
AT korolar efficacyoflatanokslatanaprost0005inpatientswithopenangleglaucoma